[1] EVANS W E，RELLING M V. Moving towards individualized medicine with pharmacogenomics[J]. Nature，2004，429(6990)：464-468. [2] WEINSHILBOUM R. Inheritance and drug response[J]. N Engl J Med，2003，348(6)：529-537. [3] BEUTLER E. Drug-induced hemolytic anemia[J]. Pharmacol Rev，1969，21(1)：73-103. [4] DE MESTIER P，DES GUETZ G. Treatment of gastrointestinal stromal tumours with imatinib Mesylate：a major breakthrough in the understanding of tumor? Specific molecular characteristics[J]. World J Surg，2005，29(3)：357-362. [5] PATEL S，ZALCBERG J R. Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours：lessons from the phase 3 trials[J]. Eur J Cancer，2008，44(4)：501-509. [6] SAVAGE D G，ANTMAN K H. Imatinib mesylate-a new oral targeted therapy[J]. N Engl J Med，2002，346(9)：683-693. [7] DEMETRI G D，MEHREN M V，BLANKE C D，et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors[J]. N Engl J Med，2002，347(7)：472-480. [8] MITSUDOMI T，YATABE Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer[J]. Cancer Sci，2007，98(12)：1817-1824. [9] SLAMON D J，GODOLPHIN W，JONES L A，et al. Studies of the HER-2/neu Proto-oncogene in human breast and ovarian cancer [J]. Science，1989，244(4905)：707-712. [10] YAMAMOTO D，IWASE S，KITAMURA K，et al. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer：Japan Breast Cancer Research Network (JBCRN) 00 Trial [J]. Cancer Chemother Pharmacol，2008，61(3)：509-514. [11] STEMMLER H J，MENGELE K，SCHMITT M，et al. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer：a case report.Anticancer[J]. Anticancer Drugs，2008，19(8)：832-836. [12] PEGRAM M，SLAMON D. Biological rationale for HER2/neu(c- erbB2) as a target for monoclonal antibody therapy[J]. Semin Oncol，2000，27 (suppl9)：13-19. [13] ROUITS E，BOISDRONCELLE M，DUMONT A，et al. Relevance of different UGT1A1 polymorphisms in irinotecaninduced toxicity：a molecular and clinical study of 75 patients[J]. Clin Cancer Res，2004，10(15)：5151-5159. [14] BEUTLER E，GELBART T，DEMINA A. Racial variability in the UDP-glucuronosyltransferase 1(UGT1A1) promoter：a balanced polymorphism for regulation of bilirubin metabolism? [J] . Proc Natl Acad Sci USA，1998，95(14)：8170-8174. [15] INNOCENTI F，GRIMSLEY C，DAS S，et al. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic group[J]. Pharmacogenetics，2002，12(9)：725-733 [16] MOCKENHAUPT M，MESSENHEIMER J，TENNIS P，et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics[J]. Neurology，2005，64(7)：1134-1138. [17] TENNIS P，STERN R S. Risk of serious cutaneous disorders after initiation of use of phenytoin，carbamazepine，or sodium valproate：a record linkage study[J]. Neurology，1997，49(2)：542-546. [18] HUNG S I，CHUNG W H，JEE S H，et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet[J]. Genomics，2006，16(4)：297-306. [19] LONJOU C，THOMAS L，BOROT N，et al. RegiSCAR Group. A marker for Stevens-Johnson syndrome：ethnicity matters[J]. Pharmacogenomics J，2006，6(4)：265-268. [20] MAN C B，KWAN P，BAUM L，et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese[J]. Epilepsia，2007，48(5)：1015-1018. [21] EL-AZHARY RA. Azathioprine：current status and future considerations[J]. Int J Dermatol， 2003，42(5)：335-341. [22] INNOCENTI F，IYER L，RATAIN M J. Pharmacogenetics：a tool for individualizing antineoplastic therapy[J]. Clin Pharmacokinet，2000，39(5)：315-325. [23] HAWWA A F，MILLERSHIP J S，COLLIER P S，et al. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine[J]. Br J Clin Pharmacol，2008，66(4)：517-528. [24] MAITLAND M L，VASISHT K，RATAIN M J. TPMT，UGT1A1 and DPYD：genotyping to ensure safer cancer therapy? [J] Trends Pharmacol Sci，2006，27(8)：432-437. [25] EL-AZHARY R A. Azathioprine：current status and future considerations[J]. Int J Dermatol， 2003，42(5)：335-341. [26] GOLDSTEIN J A. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily[J]. Br J Clin Pharmacol，2001，52(4)：349-355. [27] DESTA Z，ZHAO X，SHIN J G，et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism[J]. Clin Pharmacokinet，2002，41(12)：913-958. [28] TAMMINGA W J，WEMER J，OOSTERHUIS B，et al. The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers[J]. Eur J Clin Pharmacol，2001，57(10)：717-722. [29] FURUTA T，OHASHI K，KAMATA T，et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer[J]. Ann Intern Med，1998，129(12)：1027-1030. [30] TANIGAWARA Y，AOYAMA N，KITA T，et al. CYP2C19 Genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori[J]. Clin Pharmacol Ther，1999，66(5)：528-534.